zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2011-8-1-6zdor-1059Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEСОВРЕМЕННЫЕ ПРИНЦИПЫ КЛАССИФИКАЦИИ, ОЦЕНКИ ПРОГНОЗА И ТЕРАПИИ ПЕРВИЧНЫХ МИЕЛОДИСПЛАСТИЧЕСКИХ СИНДРОМОВMODERN PRINCIPLES OF CLASSIFICATION, PROGNOSIS AND TREATMENT OF PRIMARY MYELODYSPLASTIC SYNDROMESКлимковичН. Н.KlimkovichN. N.noemail@neicon.ruБелорусская медицинская академия последипломного образованияBelarusian Medical Academy of Post-Graduate Education201128032011013441Copyright © Климкович Н.Н., 20112011Климкович Н.Н.Klimkovich N.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1059

Статья посвящена миелодиспластическим синдромам (МДС) - группе клональных заболеваний костного мозга, в основе которых лежит патология гемопоэтических стволовых клеток, приводящая к нарушению пролиферации и дифференцировки гемопоэтических предшественников с изменением их морфологических и функциональных свойств. Описано развитие систематизации МДС по вариантам, в частности, новая классификация ВОЗ (2008). Проведена оценка использующихся прогностических параметров и систем. Представлены современные взгляды на лечение МДС с учетом индивидуализации терапии на основании факторов прогноза. Дана характеристика новых лекарственных средств и анализ результатов применения стандартных терапевтических схем в различных режимах и комбинациях.

Article is devoted myelodysplastic syndromes (MDS). It is group malignant diseases of a bone marrow in which basis the pathology hаemopoetic stem cells, leading to infringement proliferations and differentiations of hаemopoetic cells - predecessors with their change morphological and functional properties. Development of ordering MDS by variants, in particular, new classification the WHO (2008) is described. The estimation prognostic parametrs and systems is spent. Modern sights at treatment MDS with the account are presented an individualization of therapy on the basis of prognostic factors. The characteristic of new medical products and the analysis of results of application of standard therapeutic schemes in various modes and combinations is given.

миелодиспластические синдромыклассификацияпрогнозтерапияmyelodysplastic syndromesclassificationprognosistreatmentReferencesBennet, J. M. Proposals for the classification of the myelodysplastic syndromes / J. M.Bennet, D. Catovsky, M. T. Daniel // British journal of hematology. - 1982. - Vol. 51. - P. 189-199.Bennet, J. M. Proposals for the classification of the myelodysplastic syndromes / J. M.Bennet, D. Catovsky, M. T. Daniel // British journal of hematology. - 1982. - Vol. 51. - P. 189-199.TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes / O. Kosmider [et al.] // Blood. - 2009. - Vol. 114, № 15. - P. 3285-3291.TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes / O. Kosmider [et al.] // Blood. - 2009. - Vol. 114, № 15. - P. 3285-3291.Guidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Nordic MDS Group / L. Kjeldsen [et al.] // Blood. - 2010. - № 5. - 43 p.Guidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Nordic MDS Group / L. Kjeldsen [et al.] // Blood. - 2010. - № 5. - 43 p.Myelodysplastic Syndromes / A. F. List [et al.] // Hematology. - 2004. - P. 297-317.Myelodysplastic Syndromes / A. F. List [et al.] // Hematology. - 2004. - P. 297-317.Myelodysplastic syndromes/neoplasms, overview / R. D. Brunning [et al.] // In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues / Ed by S. H. Swerdlow [et al.] // Lyon: IARC. - 2008. - Vol. 2. - P. 88-93.Myelodysplastic syndromes/neoplasms, overview / R. D. Brunning [et al.] // In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues / Ed by S. H. Swerdlow [et al.] // Lyon: IARC. - 2008. - Vol. 2. - P. 88-93.Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system / O. K. Weinberg [et al.] // Blood. - 2009. - Vol. 113. - P. 1906-1908.Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system / O. K. Weinberg [et al.] // Blood. - 2009. - Vol. 113. - P. 1906-1908.Greenberg, P. International Scoring System for evaluating prognosis in myelodysplastic syndromes/ P. Greenberg [et al.] // Blood. - 1997. - Vol. 89. -P. 2079-2088.Greenberg, P. International Scoring System for evaluating prognosis in myelodysplastic syndromes/ P. Greenberg [et al.] // Blood. - 1997. - Vol. 89. -P. 2079-2088.World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes / P. Bernasconi [et al.] // British Journal of Haematology. - 2007. - Vol. 137. - P.193-205.World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes / P. Bernasconi [et al.] // British Journal of Haematology. - 2007. - Vol. 137. - P.193-205.Сравнительный анализ кариотипа пожилых больных миелодиспластическим синдромом и острым миелоидным лейкозом / С. В. Грицаев [и др.] // Клиническая онкогематология. - 2010. - Т. 3, № 2. - C. 114-118.Сравнительный анализ кариотипа пожилых больных миелодиспластическим синдромом и острым миелоидным лейкозом / С. В. Грицаев [и др.] // Клиническая онкогематология. - 2010. - Т. 3, № 2. - C. 114-118.Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group / W. R. Sperr [et al.] // Annals of Oncology. - 2010. - Vol. 21 (1). - P. 114-119.Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group / W. R. Sperr [et al.] // Annals of Oncology. - 2010. - Vol. 21 (1). - P. 114-119.Greenberg, P. L. Current therapeutic approaches for patients with myelodysplastic syndromes / P. L. Greenberg // British Journal of Haematology. - 2010. - Vol. 150, № 2. - P. 131-143.Greenberg, P. L. Current therapeutic approaches for patients with myelodysplastic syndromes / P. L. Greenberg // British Journal of Haematology. - 2010. - Vol. 150, № 2. - P. 131-143.Steensma, D. P. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies / D. P. Steensma, A. Tefferi // Leukemia Research. - 2003. - Vol. 27, № 2. - P. 95-120.Steensma, D. P. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies / D. P. Steensma, A. Tefferi // Leukemia Research. - 2003. - Vol. 27, № 2. - P. 95-120.Савченко, В. Г. Программное лечение лейкозов / В. Г. Савченко, Е. Н. Паровичникова, В. Г. Исаев. - М., 2002. - C. 166-179.Савченко, В. Г. Программное лечение лейкозов / В. Г. Савченко, Е. Н. Паровичникова, В. Г. Исаев. - М., 2002. - C. 166-179.Циклоспорин А в терапии больных рефрактерными анемиями и острыми малопроцентными лейкозами / А. В. Кохно [и др.] // Проблемы гематологии и переливания крови. - 2002. - № 1. - C. 44-45.Циклоспорин А в терапии больных рефрактерными анемиями и острыми малопроцентными лейкозами / А. В. Кохно [и др.] // Проблемы гематологии и переливания крови. - 2002. - № 1. - C. 44-45.Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment / T. M. Westers [et al.] // Blood. - 2010. - Vol. 115(9). - P. 1779-1784.Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment / T. M. Westers [et al.] // Blood. - 2010. - Vol. 115(9). - P. 1779-1784.Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the eastern cooperative oncology group (E1996) / P. L. Greenberg [et al.] // Blood. - 2009. - Vol. 114. - P. 2393-2400.Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the eastern cooperative oncology group (E1996) / P. L. Greenberg [et al.] // Blood. - 2009. - Vol. 114. - P. 2393-2400.An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach / S. Mundle [et al.] // Cancer. - 2009. - Vol. 115(4). - P. 706-715.An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach / S. Mundle [et al.] // Cancer. - 2009. - Vol. 115(4). - P. 706-715.Novel vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells / J. Hisatake [et al.] // Blood. - 2001. - Vol. 97. - P. 2427-2433.Novel vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells / J. Hisatake [et al.] // Blood. - 2001. - Vol. 97. - P. 2427-2433.Loaiza-Bonilla, A. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents / A. Loaiza-Bonilla, S. D. Gore, H. E. Carraway // Current Opinion on Hematology. - 2010. - Vol. 17(2). - P. 104-109.Loaiza-Bonilla, A. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents / A. Loaiza-Bonilla, S. D. Gore, H. E. Carraway // Current Opinion on Hematology. - 2010. - Vol. 17(2). - P. 104-109.DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes / L. Shen [et al.] // Journal of Clinical Oncology. - 2010. - Vol. 28(4). - P. 605-613.DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes / L. Shen [et al.] // Journal of Clinical Oncology. - 2010. - Vol. 28(4). - P. 605-613.Клиническая эффективность дакогена при миелодиспластическом синдроме / А. К. Голенков [и др.] // Клиническая онкогематология. - 2008. - № 4. - C. 36-40.Клиническая эффективность дакогена при миелодиспластическом синдроме / А. К. Голенков [и др.] // Клиническая онкогематология. - 2008. - № 4. - C. 36-40.Steensma, D. P. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes / D. P. Steensma, R. M. Stone // Hematology/Oncology Clinics of North America. - 2010. - Vol. 24(2). - P. 389-406.Steensma, D. P. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes / D. P. Steensma, R. M. Stone // Hematology/Oncology Clinics of North America. - 2010. - Vol. 24(2). - P. 389-406.Hematologic response to three alternative dosing schedules of Azacitidine in patients with myelodysplastic syndromes / R. M. Lyons [et al.] // Journal of Clinical Oncology. - 2009. - Vol. 27 (11). - P. 1850-1856.Hematologic response to three alternative dosing schedules of Azacitidine in patients with myelodysplastic syndromes / R. M. Lyons [et al.] // Journal of Clinical Oncology. - 2009. - Vol. 27 (11). - P. 1850-1856.Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes / A. Giagounidis [et al.] // Annals of Hematology. - 2008. - Vol. 87. - P. 345-352.Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes / A. Giagounidis [et al.] // Annals of Hematology. - 2008. - Vol. 87. - P. 345-352.Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a Randomized Phase 2 Trial by the Cancer and Leukemia Group B (CALGB 19803) / D. L. Grinblatt [et al.] // Cancer. - 2009. - Vol. 115(1). - P. 84-93.Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a Randomized Phase 2 Trial by the Cancer and Leukemia Group B (CALGB 19803) / D. L. Grinblatt [et al.] // Cancer. - 2009. - Vol. 115(1). - P. 84-93.Circulating CD33 and its clinical value in acute leukemia / A. Abdoola [et al.] // Experimental hematology. - 2010. - Vol. 38, № 6. - P. 462-471.Circulating CD33 and its clinical value in acute leukemia / A. Abdoola [et al.] // Experimental hematology. - 2010. - Vol. 38, № 6. - P. 462-471.Pagel, J. Radioimmunotherapeutic approaches for leukemia: the past, present and future / J. Pagel // Cytotherapy. - 2008. - Vol. 10 (1). - P. 13-20.Pagel, J. Radioimmunotherapeutic approaches for leukemia: the past, present and future / J. Pagel // Cytotherapy. - 2008. - Vol. 10 (1). - P. 13-20.Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation / A. Lauter [et al.] // British Journal of Haematology. - 2010. - Vol. 148 (6). - P. 910-917.Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation / A. Lauter [et al.] // British Journal of Haematology. - 2010. - Vol. 148 (6). - P. 910-917.

The authors declare that there are no conflicts of interest present.